Spasmodic Dysphonia Clinical Trial
Official title:
The Effect of Zinc Supplementation Prior to Botulinum Neurotoxin Type A Injection in the Treatment of Spasmodic Dysphonia
One initial study has shown that Botulinum Toxin (BT) in combination with zinc supplementation may increase the duration of effects BT treatment. This initial study was in the context of facial aesthetics. The purpose of the present study is to determine the effect, if any, of oral zinc supplementation prior to BT in the treatment of spasmodic dysphonia. If positive effects will be observed, this would help reduce the burden of disease for these patients.
Botulinum toxin (BT) injections are commonly used to treat various cosmetic, muscular, anesthetic, and neurologic pathologies. In 2012, one study suggested that a combination of zinc and phytase supplementation could increase the duration and degree of effects of botulinum neurotoxin type A (BoNTA). However, this study was met with scientific skepticism due to concerns of financial conflicts of interest, unmasking the study too early, and ambiguity of the dosage of zinc used. In 2021, a new study with 25 patients receiving BoNTA injections for the treatment of excessive gingival display (EGD), showed that zinc supplementation prolonged the effect of BoNTA with statistical significance. There has been no further studies or commentary since these latest results were published. The purpose of this study is to test if the effect of zinc supplementation on BoNTA can be replicated and also translated to a different disease process that is also treated with BT-spasmodic dysphonia (SD). If positive effects are discovered, this would strengthen the preliminary results of the 2021 study, encourage future larger studies on the same hypothesis, and, ultimately, could lead to reducing the burden of disease for patients with SD and any other condition that is treated with BT injections. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06111027 -
Usability of Vibro-tactile Stimulation to Treat Spasmodic Dysphonia
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02061943 -
Examining the Spasmodic Dysphonia Diagnosis and Assessment Procedure (SD-DAP) for Measuring Symptom Change
|
N/A | |
| Recruiting |
NCT05158166 -
DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05580302 -
Cortical Silent Period in Laryngeal Dystonia
|
||
| Recruiting |
NCT05150106 -
Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor
|
||
| Recruiting |
NCT05216770 -
Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor
|
Early Phase 1 | |
| Recruiting |
NCT05150093 -
Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor
|
N/A | |
| Completed |
NCT00713414 -
Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia
|
||
| Completed |
NCT01961297 -
Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response
|
Phase 2 | |
| Completed |
NCT00118586 -
Neuropathology of Spasmodic Dysphonia
|
||
| Not yet recruiting |
NCT04938154 -
A Phase 2 Trial of Deep Brain Stimulation for Spasmodic Dysphonia
|
Phase 2 | |
| Active, not recruiting |
NCT03292458 -
Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor
|
Phase 2/Phase 3 | |
| Completed |
NCT02957942 -
rTMS in Spasmodic Dysphonia
|
N/A | |
| Completed |
NCT02558634 -
Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial
|
N/A | |
| Terminated |
NCT00895063 -
Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia
|
N/A | |
| Completed |
NCT05158179 -
Assessment of Laryngopharyngeal Sensation in Adductor Spasmodic Dysphonia
|
N/A | |
| Not yet recruiting |
NCT06078527 -
Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort
|
N/A | |
| Completed |
NCT04648891 -
Spasmodic Dysphonia Pain
|
Phase 2/Phase 3 | |
| Completed |
NCT03042962 -
Brain Networks in Dystonia
|
||
| Completed |
NCT03746509 -
Laryngeal Vibration for Spasmodic Dysphonia
|
N/A |